Global Oncology Biosimilars market to grow at a CAGR of 29.87 percent over the period 2013-2018

PORTLAND, Ore. - July 21, 2015 - PRLog -- About Oncology Biosimilars

Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.

The Global Oncology Biosimilars market to grow at a CAGR of 29.87 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Oncology Biosimilars market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales biosimilars used in cancer treatment.

Global Oncology Biosimilars Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Oncology Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Get More Details At: http://www.bigmarketresearch.com/global-oncology-biosimil...

Key Regions

• Americas

• APAC

• EMEA

Key Vendors

• Biocon

• Celltrion

• Dr. Reddy's Laboratories

• Hospira

• Mylan

• Sandoz

Other Prominent Vendors

• 3SBio

• Abbvie

• AstraZeneca

• BioXpress Therapeutics

• Boehringer Ingelheim

• Coherus Biosciences

• Intas Pharmaceuticals

• Merck Serono

• Pfizer

• Wockhardt

Market Driver

• Increased Number of Patent Expirations

• For a full, detailed list, view our report

Market Challenge

• Risks Related to Drug Failure

• For a full, detailed list, view our report

Market Trend

• Outsourcing of Biosimilar Manufacturing

• For a full, detailed list, view our report?